5-(5-bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(5-bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide
• 英文别名: 5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-ethyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide；N-piperidinyl-5-(5-bromo-thiophen-2-yl)-1-(2',4'-dichloro phenyl)-4-ethyl-1H-pyrazol-3-carboxamide；N-piperidinyl-5-(5-bromo-thiophen-2-yl)-1-(2',4'-dichlorophenyl)-4-ethyl-1H-pyrazol-3-carboxamide；5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide；5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-ethyl-N-piperidin-1-ylpyrazole-3-carboxamide
• 化学式: C₂₁H₂₁BrCl₂N₄OS
• 分子量: 528.3
• InChiKey: VXJZFSDRFQFZOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(5-bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide 、 4-乙炔基-α,α,α-三氟甲苯 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 C.I.酸性橙108 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以86%的产率得到1-(2,4-二氯苯基)-4-乙基-N-1-哌啶基-5-[5-[2-[4-(三氟甲基)苯基]乙炔基]-2-噻吩基]-1H-吡唑-3-羧酰胺
  参考文献：
  名称：

  Discovery of 1-(2,4-Dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a Potential Peripheral Cannabinoid-1 Receptor Inverse Agonist

  摘要：

  DOI：

  10.1002/cmdc.201000246
• 作为产物：
  描述：

  5-(5-Bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-carboxylic acid 、 1-氨基哌啶 在 1-羟基苯并三唑一水物 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 5-(5-bromo-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide
  参考文献：
  名称：

  Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a cb1 receptor antagonist with in vivo antiobesity effect

  摘要：

  A few thienyl substituted pyrazole derivatives were synthesized to aid in the characterization of the cannabinoid receptor antagonist and also to serve as potentially useful antiobesity agent. Structural requirements for selective CB1 receptor antagonistic activity of 5-thienyl pyrazole derivatives included the structural similarity with potent, specific antagonist rimonabant 1. Compound 3 has been identified as a hair growth stimulator and an antiobesity agent in animal models. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.03.046

文献信息

• SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS
  申请人：Xia Mingde

  公开号：US20070117858A1

  公开（公告）日：2007-05-24

  This invention is directed to a substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulator compound of formula (I): or a form thereof, and methods for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.

  这项发明涉及一种式（I）的取代5-杂环芳基-1-苯基-吡唑酮类大麻素调节剂化合物，或其形式，以及用于治疗、改善或预防大麻素受体介导的综合征、疾病或疾病的方法。
• Pharmaceutical compounds
  申请人：Lazzari Paolo

  公开号：US20050261281A1

  公开（公告）日：2005-11-24

  Pyrazole derivatives of the following formula (I), having affinity for the cannabinoidergic CB1 and/or CB2 receptors: wherein: R is a group selected from: C 1 -C 10 alkyl; aryl, arylalkyl or arylalkenyl, not substituted or having from one to four substituents, equal to or different from each other; A is a group selected from the following: an ether group of formula —(CH 2 )—O—(CH 2 ) v —R″ wherein v is equal to 1 or 2; R″ is as defined in the present application; a ketone group of formula —C(O)-Z′, wherein Z′ is as defined in the present application; a substituent having an hydroxyl function of formula —CH(OH)-Z′, Z′ being as defined in the present application; Description of the industrial invention in the name of: NEUROSCIENZE S.c. a r.l., of Italian nationality, with head office in Cagliari, via Palabanda 9.

  以下式子（I）的吡唑衍生物具有对大麻素受体CB1和/或CB2的亲和力：其中：R是以下组中选择的一组：C1-C10烷基；芳基，芳基烷基或芳基烯基，未取代或具有一个到四个取代基，相互相同或不同；A是以下组中选择的一组：化学式为—（CH2）-O-（ ）v-R″的醚基，其中v等于1或2；R″如本申请所定义；化学式为—C（O）-Z′的酮基，其中Z′如本申请所定义；具有羟基功能的取代基，化学式为—CH（OH）-Z′，其中Z′如本申请所定义；该工业发明的描述以NEUROSCIENZE S.c. a r.l.的名义进行，该公司是意大利国籍，总部位于卡利亚里，Palabanda 9号。
• PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS
  申请人：NEUROSCIENZE PHARMANESS S.C. a R.L.

  公开号：EP1602656A1

  公开（公告）日：2005-12-07

  Pyrazole derivatives of the following formula (I), having affinity for the cannabinoidergic CB1 and/or CB2 receptors:    wherein: R is a group selected from: C1-C10 alkyl; aryl, arylalkyl or arylalkenyl, not substituted or having from one to four substituents, equal to or different from each other; A is a group selected from the following: an ether group of formula -(CH2)-O-(CH2)v-R" wherein    - v is equal to 1 or 2;    - R" is as defined in the present application; a ketone group of formula -C(O)-Z', wherein Z' is as defined in the present application; a substituent having an hydroxyl function of formula -CH(OH)-Z', Z' being as defined in the present application; an amide substituent of formula -C(O)-NH-T', T' being as defined in the present application; B is a group as defined in the present application; D is an heteroaryl optionally substituted.

  对大麻素能 CB1 和/或 CB2 受体具有亲和力的下式 (I) 吡唑衍生物： 其中 R 是选自以下各项的基团 C1-C10 烷基 芳基、芳烷基或芳烯基，未被取代或具有一至四个相互等同或不同的取代基； A 是选自以下的基团 式中的醚基-(CH2)-O-( )v-R" 其中 - v 等于 1 或 2； - R "如本申请中所定义； 式-C(O)-Z'的酮基，其中 Z'如本申请中所定义； 式-CH(OH)-Z'的具有羟基官能团的取代基，其中 Z'定义如本申请所 述； 式-C(O)-NH-T'的酰胺取代基，T'如本申请中所定义； B 是本申请中所定义的基团； D 是任选取代的杂芳基。
• EP1602656B1
  申请人：——

  公开号：EP1602656B1

  公开（公告）日：2011-06-29
• PHARMACEUTICAL COMPOUNDS
  申请人：Lazzari Paolo

  公开号：US20100105896A1

  公开（公告）日：2010-04-29

  Pyrazole derivatives of the following formula (I), having affinity for the cannabinoidergic CB1 and/or CB2 receptors: wherein: R is a group selected from C 1 -C 10 alkyl; aryl, arylalkyl or arylalkenyl, not substituted or having from one to four substituents, equal to or different from each other; A is a group selected from the following: an ether group of formula —(CH 2 )—O—(CH 2 ) v —R″ wherein v is equal to 1 or 2; R″ is as defined in the present application; a ketone group of formula —C(O)—Z′, wherein Z′ is as defined in the present application; a substituent having an hydroxyl function of formula —CH(OH)—Z′, being as defined in the present application; an amide substituent of formula —C(O)—NH-T′, T′ being as defined in the present application; B is a group as defined in the present application; D is an heteroaryl optionally substituted.